enfortumab vedotin-ejfv - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Eli Lilly’s retatrutide moves closer to a planned 2027 U.S. filing after completing its core Phase 3 programme for obesity, knee pain and sleep apnea. Representative image.

Retatrutide development: Phase 3 results, 2027 FDA filing, TRIUMPH trials and what comes next

India and Canada are accelerating CEPA negotiations as LNG, nuclear energy and critical minerals become central to their expanding economic relationship. Representative image.

Canada targets India trade deal by year-end as LNG, nuclear and critical minerals talks deepen

The White House press-access dispute intensified after MS NOW journalists said their credentials were disabled following Donald Trump’s media ban. Representative image.

Trump White House media ban takes effect as MS NOW journalists are turned away

Smoke near Riyadh’s King Khalid International Airport followed Saudi aerial danger alerts as the conflict with Yemen’s Houthis intensifies. Representative image.

Smoke rises near Riyadh airport after Saudi aerial alerts as Houthi conflict escalates

Pfizer, Astellas Pharma and Merck secure expanded U.S. FDA approval for Padcev plus Keytruda in muscle-invasive bladder cancer treatment. Representative image.

Read More

Pharma Industry News

Pfizer (PFE), Merck (MRK) win FDA expansion for Padcev plus Keytruda in all MIBC patients

Pfizer (PFE) Padcev+Keytruda MIBC label expands to all patients as first platinum-free regimen; AstraZeneca's Imfinzi cisplatin-only slot loses ground.

July 12, 2026

web analytics